Abstract
With the widespread application of computed tomography and lung cancer screening, multiple primary lung cancers (MPLCs) are increasing in our daily practice. However, MPLC is characterized with highly heterogeneous immune profile, hindering the application of immune checkpoint inhibitors (ICIs). A better understanding of the immune profiling of MPLCs is urgently needed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
